CD4 mimic compound with anti-HIV activity

DE602020051835T2Active Publication Date: 2025-05-21INSTITUTE OF SCIENCE TOKYO +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
DE602020051835
Authority / Receiving Office
DE · DE
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-10-29
Publication Date
2025-05-21
Estimated Expiration
2040-10-29

AI Technical Summary

Technical Problem

Current anti-HIV drugs, such as NBD-556, have low anti-HIV activity, high cytotoxicity, and poor pharmacokinetics, leading to ineffective long-term treatment and the emergence of drug-resistant viruses.

Method used

Development of novel CD4 mimic compounds, like YIR-821 derivatives with PEG or alkyl chains, which exhibit enhanced anti-HIV activity, reduced cytotoxicity, and extended half-life, inhibiting HIV entry by binding to gp120 and exposing the V3 loop, thereby preventing viral fusion.

Benefits of technology

The CD4 mimic compounds demonstrate significantly improved anti-HIV activity with low cytotoxicity and prolonged half-life, potentially reducing treatment costs and duration by maintaining efficacy over a longer period.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided is a CD4 mimic compound having an improved efficacy for anti-HIV treatment and a more improved pharmacokinetics. There is provided a compound represented by the following formula (I): wherein R1 represents C2H4(OC2H4)n-OCH3 or CmH2m+1; R2 represents O or NH; n is 3 to 25; and m is 4 to 22, or a salt thereof, and an HIV infection inhibitor comprising the compound or a salt thereof as an active ingredient.
Need to check novelty before this filing date? Find Prior Art